Dutta Aloke K, Venkataraman Sylesh K, Fei Xiang-Shu, Kolhatkar Rohit, Zhang Shijun, Reith Maarten E A
Wayne State University, Department of Pharmaceutical Sciences, Applebaum College of Pharmacy and Health Science, RM# 3128, Detroit, MI 48202, USA.
Bioorg Med Chem. 2004 Aug 15;12(16):4361-73. doi: 10.1016/j.bmc.2004.06.019.
In a recent preliminary communication we described the development of a series of hybrid molecules for the dopamine D2 and D3 receptor subtypes. The design of these compounds was based on combining pharmacophoric elements of aminotetralin and piperazine molecular fragments derived from known dopamine receptor agonist and antagonist molecules. Molecules developed from this approach exhibited high affinity and selectivity for the D3 receptor as judged from preliminary [(3)H]spiperone binding data. In this report, we have expanded our previous finding by developing additional novel molecules and additionally evaluated functional activities of these novel molecules in the [(3)H]thymidine incorporation mitogenesis assay. The binding results indicated highest selectivity in the bioisosteric benzothiazole derivative N6-[2-(4-phenyl-piperazin-1-yl)-ethyl]-N6-propyl-4,5,6,7-tetrahydro-benzothiazole-2,6-diamine (14) for the D3 receptor whereas the racemic compound 7-([2-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-ethyl]-propyl-amino)-5,6,7,8-tetrahydro-naphthalen-2-ol (10c) showed the strongest potency. Mitogenesis studies to evaluate functional activity demonstrated potent agonist properties in these novel derivatives for both D2 and D3 receptors. In this regard, compound 7-[[4-(4-phenyl-piperazin-1-yl)-butyl]-prop-2-ynyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol (7b) exhibited the most potent agonist activity at the D3 receptor, 10 times more potent than quinpirole and was also the most selective compound for the D3 receptor in this series. Racemic compound 10a was resolved; however, little separation of activity was found between the two enantiomers of 10a. The marginally more active enantiomer (-)-10a was examined in vivo using the 6-OH-DA induced unilaterally lesioned rat model to evaluate its activity in producing contralateral rotations. The results demonstrated that in comparison to the reference compound apomorphine, (-)-10a was quite potent in inducing contralateral rotations and exhibited longer duration of action.
在最近的一篇初步通讯中,我们描述了一系列针对多巴胺D2和D3受体亚型的杂合分子的研发情况。这些化合物的设计基于将氨基四氢萘和哌嗪分子片段的药效基团元素相结合,这些片段源自已知的多巴胺受体激动剂和拮抗剂分子。根据初步的[³H]螺哌隆结合数据判断,通过这种方法开发的分子对D3受体表现出高亲和力和选择性。在本报告中,我们通过开发更多新型分子扩展了之前的发现,并在[³H]胸苷掺入促有丝分裂试验中额外评估了这些新型分子的功能活性。结合结果表明,生物电子等排体苯并噻唑衍生物N6-[2-(4-苯基-哌嗪-1-基)-乙基]-N6-丙基-4,5,6,7-四氢-苯并噻唑-2,6-二胺(14)对D3受体具有最高的选择性,而外消旋化合物7-([2-[4-(2,3-二氯-苯基)-哌嗪-1-基]-乙基]-丙基-氨基)-5,6,7,8-四氢-萘-2-醇(10c)显示出最强的效力。评估功能活性的促有丝分裂研究表明,这些新型衍生物对D2和D3受体均具有强效激动剂特性。在这方面,化合物7-[[4-(4-苯基-哌嗪-1-基)-丁基]-丙-2-炔基-氨基]-5,6,7,8-四氢-萘-2-醇(7b)在D3受体上表现出最有效的激动剂活性,比喹吡罗强10倍,也是该系列中对D3受体最具选择性的化合物。外消旋化合物10a被拆分;然而,在10a的两种对映体之间几乎没有发现活性差异。使用6-OH-DA诱导的单侧损伤大鼠模型在体内检测了活性稍高的对映体(-)-10a,以评估其产生对侧旋转的活性。结果表明,与参考化合物阿扑吗啡相比,(-)-10a在诱导对侧旋转方面相当有效,并且作用持续时间更长。